<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40852343</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0971-9202</ISSN><JournalIssue CitedMedium="Print"><Volume>75</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of obstetrics and gynaecology of India</Title><ISOAbbreviation>J Obstet Gynaecol India</ISOAbbreviation></Journal><ArticleTitle>Maternal and Fetal Outcomes in Gestational Diabetes Mellitus Treated with Metformin with or Without Insulin.</ArticleTitle><Pagination><StartPage>304</StartPage><EndPage>310</EndPage><MedlinePgn>304-310</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13224-025-02124-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Gestational Diabetes Mellitus (GDM) is linked with a multitude of adverse perinatal outcomes. There is a want for standard guidelines regarding the usage of Metformin in GDM. We aimed to study the perinatal outcomes in women diagnosed with GDM treated primarily with Metformin with or without Insulin.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a randomized controlled pilot study. with a total of 75 women, divided into three groups: GDM treated with Metformin with or without Insulin (Group M), GDM on Insulin alone (Group I), and healthy pregnant women as controls (Group H), with 25 subjects in each group. At delivery, fetal and maternal outcomes were documented.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The mean age in groups M, I and H were 27.4, 26.2, and 27.3 years respectively. The baseline mean HOMA-IR were 3.9 and 4.1 for Group M and Group I, respectively (<i>p</i>-0.560). The mean fetal birth weight was 2.95&#x2009;&#xb1;&#x2009;0.54&#xa0;kg, 2.8&#x2009;&#xb1;&#x2009;0.41&#xa0;kg, and 2.97&#x2009;&#xb1;&#x2009;0.65&#xa0;kg in Groups M, H, and I, respectively (<i>p</i>&#x2009;=&#x2009;0.527). The mean newborn HOMA-IR in Groups M and I was 1.8&#x2009;&#xb1;&#x2009;0.4 and 1.7&#x2009;&#xb1;&#x2009;0.5, respectively (<i>p</i>&#x2009;=&#x2009;0.185). The adverse events in newborns were 20% (<i>n</i>&#x2009;=&#x2009;5), 16% (<i>n</i>&#x2009;=&#x2009;4) and 16% (<i>n</i>&#x2009;=&#x2009;4) in Groups M, H, and I respectively (<i>p</i>&#x2009;=&#x2009;0.403). The incidence of caesarean deliveries was 40% (<i>n</i>&#x2009;=&#x2009;10), 48% (<i>n</i>&#x2009;=&#x2009;12) and 24% (<i>n</i>&#x2009;=&#x2009;6) in Groups M, H, and I respectively (<i>p</i>-0.253).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The study revealed identical maternal and fetal outcomes in women treated with Metformin as the primary drug compared to conventional treatment with Insulin in GDM.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Abhinav</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6663-2586</Identifier><AffiliationInfo><Affiliation>Armed Forces Medical College, Pune, 411040 India.</Affiliation><Identifier Source="ROR">https://ror.org/05g6w6j42</Identifier><Identifier Source="GRID">grid.413909.6</Identifier><Identifier Source="ISNI">0000 0004 1766 9851</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muthukrishnan</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, AFMC, Pune, India.</Affiliation><Identifier Source="ROR">https://ror.org/05g6w6j42</Identifier><Identifier Source="GRID">grid.413909.6</Identifier><Identifier Source="ISNI">0000 0004 1766 9851</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Ankita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Military Hospital, Trivandrum, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiran</LastName><ForeName>Burle Chaitanya</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Medicine, INHS Kalyani, Visakhapatnam, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>J Obstet Gynaecol India</MedlineTA><NlmUniqueID>0374763</NlmUniqueID><ISSNLinking>0975-6434</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fetal Outcomes</Keyword><Keyword MajorTopicYN="N">Gestational Diabetes Mellitus</Keyword><Keyword MajorTopicYN="N">HOMA-IR</Keyword><Keyword MajorTopicYN="N">Insulin</Keyword><Keyword MajorTopicYN="N">Maternal outcomes</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword></KeywordList><CoiStatement>Conflict of interestNil.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>25</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>25</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>25</Day><Hour>5</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40852343</ArticleId><ArticleId IdType="pmc">PMC12367571</ArticleId><ArticleId IdType="doi">10.1007/s13224-025-02124-6</ArticleId><ArticleId IdType="pii">2124</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mantri N, Goel AD, Patel M, et al. National and regional prevalence of gestational diabetes mellitus in India: a systematic review and Meta-analysis. BMC Public Health. 2024;24:527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10877914</ArticleId><ArticleId IdType="pubmed">38378536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajani TT, Rahman MT, Karim MR. Maternal and fetal outcome of mothers with gestational diabetes mellitus attending BIRDEM Hospital. Mymensingh Med J. 2014;23:290&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24858157</ArticleId></ArticleIdList></Reference><Reference><Citation>Benhalima K, Devlieger R, Van Assche A. Screening and management of gestational diabetes. Best Pract Res Clin Obstet Gynaecol. 2015;29:339&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">25457858</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiswick C, Reynolds RM, Denison F, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3:778&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4673088</ArticleId><ArticleId IdType="pubmed">26165398</ArticleId></ArticleIdList></Reference><Reference><Citation>Huhtala MS, Tertti K, Juhila J, Sorsa T, R&#xf6;nnemaa T. Metformin and insulin treatment of gestational diabetes: effects on inflammatory markers and IGF-binding protein-1 &#x2013; secondary analysis of a randomized controlled trial. BMC Pregnancy Childbirth. 2020;20:401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7353798</ArticleId><ArticleId IdType="pubmed">32652973</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath RT, Glastras SJ, Scott ES, Hocking SL, Fulcher GR. Outcomes for women with gestational diabetes treated with metformin: a retrospective, Case Control Study. J Clin Med. 2018;7:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867576</ArticleId><ArticleId IdType="pubmed">29522471</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves C, Cunha F, Martinho M, et al. Metformin combined with insulin in women with gestational diabetes mellitus: a propensity score-matched study. Acta Diabetol. 2021;58:615&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">33459895</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao LX, Shi WT, Han YX. Metformin versus insulin for gestational diabetes: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2021;34:2741&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">31558075</ArticleId></ArticleIdList></Reference><Reference><Citation>Landi SN, Radke S, Boggess K, et al. Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand. Pharmacoepidemiol Drug Saf. 2019;28:1609&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">31693269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainuddin J, Karim N, Hasan AA, Naqvi SA. Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. Diabetes Res Clin Pract. 2015;107:290&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25467617</ArticleId></ArticleIdList></Reference><Reference><Citation>Balani J, Hyer SL, Rodin DA, Shehata H. Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study. Diabet Med. 2009;26:798&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">19709150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>